Other anti-HER2 therapies include HER2-amplified NSCLC patients, such as T-DM1, which shows an ORR of 55% in 14 HER2-amplified patients enrolled in a phase II basket trial and pyrotinib, which also showed an ORR of 22.2% and a mPFS of 6.3 months in 22 patients (20, 34). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.